Midgard Science
R

Rafarm

Athens, Greecerafarmgroup.comFrom their website, Nov 2026

Work here? Claim this listing

About

RAFARM is a pharmaceutical company in Greece that develops, manufactures, and supplies complex sterile products, especially ophthalmics and injectables. It serves partners in CDMO, CMO, and out-licensing models, and also sells products in Greece and Cyprus. Its activities are centered at RAFARM Campus in Attica, Greece.

Services

  • R&D and product development

    Designs process-development strategies, evaluates API suppliers, applies QbD, and develops pharmaceutical products in collaboration with customers.

  • Non-clinical and stability studies

    Designs and implements non-clinical in-vitro studies and executes stability studies.

  • Technology transfer

    Provides technology transfer activities as part of development support.

  • Dossier and registration support

    Develops product dossiers and supports registration processes, including upgrading older dossiers to current standards.

  • Manufacturing

    Provides end-to-end contract manufacturing services for ophthalmic and injectable products.

  • Scale-up and commercial manufacturing

    Supports product scale-up in manufacturing and transition from development to commercial scale.

  • Quality control and quality assurance

    Operates quality control and assurance activities across development, production, and distribution under a Quality Management System.

  • Regulatory affairs

    Monitors pharmaceutical legislation, advises on legal and scientific requirements, and secures and maintains marketing authorizations.

10 more services
  • Out-licensing and supply
  • B2C commercial supply in Greece and Cyprus
  • Development and production of sterile ophthalmic products
  • Development and production of complex injectable products
  • Value Added Medicines development
  • Process development
  • Non-clinical study support
  • Stability studies
  • Product dossier development
  • Manufacturing problem solving

Capabilities

Assays and studies
  • Process development
  • Stability studies
  • Non-clinical in-vitro studies
  • Quality control
  • Quality assurance
  • In-vitro studies
Scale and capacity
  • Annual Capacity (1 shift): 300,000,000 tablets
  • Annual Capacity (1 shift): 15,000,000 vials
  • Annual Capacity (1 shift): 10,000,000 ampoules
  • Annual Capacity (1 shift): 40,000,000 units of ophthalmic products
  • >1,350 own development pharmaceutical products
  • >100 products with regulatory approval worldwide
  • 12 ANDA approvals from FDA
Therapeutic areas
  • Ophthalmology
  • Glaucoma
  • Ocular hypertension
  • Inflammation and pain after cataract surgery
  • Inflammatory conditions of the anterior segment of the eye
  • Anterior uveitis
  • Antiallergic
  • Bacterial external ocular infections

Instruments and platforms

  • BMS – Building Management System

Modalities and species

Modalities
Small molecule

Details

Type
CDMO
Quality
GMP (Good Manufacturing Practice) (manufacturing facilities) · cGMPs (quality management system) · EU GMP (successful inspections) · US FDA (successful inspections) · Russia FMBA (successful inspections) · Canada HC (successful inspections) · Taiwan authorities (successful inspections) · Tunisian authorities (successful inspections) · Saudi Arabia authorities (successful inspections) · Korea authorities (successful inspections) · Greek National Organization for medicine (successful inspections)
Based in
Athens, Greece
Sites
Attica, Greece · Neo Psychiko, Greece
Serves
Worldwide, USA, Canada, Europe, Middle East, Greece, Cyprus

Public records

Parent company
RAFARM UK LIMITED · GB GLEIF
FDA drug establishment registration
3009592290 · MANUFACTURE source

Similar labs